{"transactions":[{"id":1920103,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:17:22.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-024386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024386/doc4.xml","form_type":"4"}},{"id":1920102,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:17:22.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":61853,"source":{"system":"sec-edgar","filing":"0001209191-23-024386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024386/doc4.xml","form_type":"4"}},{"id":1998221,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-23T22:11:20.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-012271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123012271/doc4.xml","form_type":"4"}},{"id":2043315,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1140},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043314,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043313,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043312,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":49,"price":5.09,"value":249.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":11853,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043311,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"sale","acquired":false,"shares":1648,"price":5.0796,"value":8371.1808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":11902,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043310,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":13550,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043309,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":12410,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043308,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":10010,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2047138,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047137,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":519},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047136,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":1066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1066},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047135,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047134,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":7,"price":5.3101,"value":37.1707,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":7610,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047133,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":1302,"price":5.3383,"value":6950.4666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":7617,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047132,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":8919,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047131,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6519,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047130,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":1066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047129,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4934,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2091805,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":519,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":262},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091804,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":1066,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":534},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091803,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."}],"balance_after":380,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091802,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091801,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":910,"price":4.775,"value":4345.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":4554,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091800,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":5464,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091799,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":5202,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091798,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4668,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091797,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4288,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2313732,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Performance Stock Units","published_at":"2022-03-31T21:15:20.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":120000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-22-021792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021792/doc4.xml","form_type":"4"}},{"id":2317385,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-03-28T11:00:13.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":120000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-22-021209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021209/doc4.xml","form_type":"4"}},{"id":2490100,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2021-12-02T11:30:09.000Z","date":"2021-11-30","kind":"exercise","acquired":false,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":115000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-21-067391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121067391/doc4.xml","form_type":"4"}},{"id":2490099,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Common Stock","published_at":"2021-12-02T11:30:09.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":29790,"price":0.5353,"value":15946.587,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $0.4819 to $0.5503 for an average weighted sale price of $0.5353. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":99368,"source":{"system":"sec-edgar","filing":"0001209191-21-067391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121067391/doc4.xml","form_type":"4"}},{"id":2490098,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Common Stock","published_at":"2021-12-02T11:30:09.000Z","date":"2021-11-30","kind":"exercise","acquired":true,"shares":115000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021."}],"balance_after":129158,"source":{"system":"sec-edgar","filing":"0001209191-21-067391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121067391/doc4.xml","form_type":"4"}},{"id":2555515,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:39.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":5.16,"exercise_date":"2019-03-15","expiration_date":"2028-03-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-058498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058498/doc4.xml","form_type":"4"}},{"id":2555514,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:39.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":6.83,"exercise_date":"2018-03-15","expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-058498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058498/doc4.xml","form_type":"4"}},{"id":2555513,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:39.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Underlying shares were subject to vesting as follows: equal monthly installments over 12 months."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Underlying shares were subject to vesting as follows: equal monthly installments over 12 months."}],"balance_after":0,"derivative":{"exercise_price":8.92,"exercise_date":"2016-01-17","expiration_date":"2025-12-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-058498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058498/doc4.xml","form_type":"4"}},{"id":2555512,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:39.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":5.01,"exercise_date":"2015-07-09","expiration_date":"2024-07-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-058498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058498/doc4.xml","form_type":"4"}},{"id":2555511,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2021-10-01T21:00:39.000Z","date":"2021-09-29","kind":"grant","acquired":true,"shares":38954,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the \"Option Exchange Program\"). Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":38954,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":38954},"source":{"system":"sec-edgar","filing":"0001209191-21-058498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058498/doc4.xml","form_type":"4"}},{"id":2646976,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP Finance"}}],"security":"Restricted Stock Units","published_at":"2021-07-02T21:42:35.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":80000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001387131-21-007114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007114/ownership.xml","form_type":"4"}},{"id":2646975,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP Finance"}}],"security":"Performance Stock Units","published_at":"2021-07-02T21:42:35.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":160000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001387131-21-007114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007114/ownership.xml","form_type":"4"}},{"id":2717900,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP Finance"}}],"security":"Restricted Stock Units","published_at":"2021-05-13T00:44:26.000Z","date":"2021-05-10","kind":"exercise","acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":38000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001387131-21-005571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005571/ownership.xml","form_type":"4"}},{"id":2717899,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP Finance"}}],"security":"Common Stock","published_at":"2021-05-13T00:44:26.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":4842,"price":1.04,"value":5035.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":14158,"source":{"system":"sec-edgar","filing":"0001387131-21-005571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005571/ownership.xml","form_type":"4"}},{"id":2717898,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and VP Finance"}}],"security":"Common Stock","published_at":"2021-05-13T00:44:26.000Z","date":"2021-05-10","kind":"exercise","acquired":true,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001387131-21-005571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005571/ownership.xml","form_type":"4"}},{"id":2965624,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2020-11-27T22:09:30.000Z","date":"2020-11-24","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in two equal installments on November 24, 2021 and November 24, 2022."}],"balance_after":230000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001387131-20-010309","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120010309/ownership.xml","form_type":"4"}},{"id":3190252,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President Finance"}}],"security":"Restricted Stock Units","published_at":"2020-04-02T00:30:46.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."}],"balance_after":57000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0001387131-20-003589","document":"donegan-form4_033020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120003589/donegan-form4_033020.xml","form_type":"4"}},{"id":3190251,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President Finance"}}],"security":"Performance Stock Units","published_at":"2020-04-02T00:30:46.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":57000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0001387131-20-003589","document":"donegan-form4_033020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120003589/donegan-form4_033020.xml","form_type":"4"}},{"id":3426478,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-08-31T01:50:27.000Z","date":"2019-08-28","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Underlying shares vest as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant."}],"balance_after":120000,"derivative":{"exercise_price":2.73,"exercise_date":"2020-08-28","expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001387131-19-006607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713119006607/ownership.xml","form_type":"4"}},{"id":3991461,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President Finance"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-03-19T21:45:21.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Underlying shares vest as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":5.16,"exercise_date":"2019-03-15","expiration_date":"2028-03-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001387131-18-001125","document":"donegan-form4_031518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713118001125/donegan-form4_031518.xml","form_type":"4"}},{"id":4381753,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President Finance"}}],"security":"Non-qualified stock option (right to buy)","published_at":"2017-03-17T22:31:04.000Z","date":"2017-03-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Underlying shares vest as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant."}],"balance_after":40000,"derivative":{"exercise_price":6.83,"exercise_date":"2018-03-15","expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001387131-17-001455","document":"donegan-form4_031517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117001455/donegan-form4_031517.xml","form_type":"4"}}]}